Frederick Wayne Holtsberg

Title: The Innovations of Frederick Wayne Holtsberg

Introduction

Frederick Wayne Holtsberg is an accomplished inventor based in Nicholasville, KY (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents. With a total of 2 patents, his work focuses on addressing critical health issues related to uric acid levels and cancer treatment.

Latest Patents

Holtsberg's latest patents include a PEG-modified uricase, which is designed to treat various illnesses characterized by increased circulating uric acid levels, such as hyperuricemia and tumor lysis syndrome. This innovative approach utilizes polyethylene glycol to enhance the efficacy of uricase. Another notable invention is a mutated form of arginine deiminase, which has been genetically modified for more efficient manufacturing and processing. This invention also encompasses recombinant DNA molecules, vectors, and therapeutic compositions aimed at treating cancer and other disease states.

Career Highlights

Throughout his career, Holtsberg has worked with notable companies, including Phoenix Pharmacologics, Inc. and Phoenix Pharmacologies, Inc. His expertise in biotechnology has allowed him to contribute to advancements in drug development and therapeutic solutions.

Collaborations

Holtsberg has collaborated with esteemed colleagues such as Charles Mark Ensor and Mike A Clark, further enhancing the impact of his work in the field.

Conclusion

Frederick Wayne Holtsberg's innovative contributions to biotechnology demonstrate his commitment to improving health outcomes through his inventions. His patents reflect a deep understanding of the challenges in treating diseases related to uric acid and cancer, showcasing his role as a significant figure in the field.